Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma.

Cancer Immunol Immunother · 2021 · PMC8571215 · PMID 33956203

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

A numerical trend towards higher intra-patient variation of sPD-L1 levels was observed in patients who received bevacizumab 10 mg/kg body weight as compared to patients where 400 mg bevacizumab were administered ( p = 0.103, Mann–Whitney U test).

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.